Eli Lilly (LLY)
(Delayed Data from NYSE)
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$887.16 USD
+1.61 (0.18%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth A Momentum F VGM
Zacks News
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $574.96, marking a +0.64% move from the previous day.
Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod
by Zacks Equity Research
Pfizer (PFE) gets marketing authorization in the EU for Litfulo to treat adults and adolescent patients aged 12 years and older with severe alopecia areata.
Should Invesco Large Cap Growth ETF (PWB) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PWB
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWB
Novo Nordisk (NVO) Announces Stock Split to Enhance Liquidity
by Zacks Equity Research
Novo Nordisk (NVO) conducts a two-for-one stock split. While this is already in effect at the stock exchange in Denmark, the ADRs listed on the NYSE will be split in the same ratio by next week.
Nektar (NKTR) Up on Positive New Data From Eczema Study
by Zacks Equity Research
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
Is Franklin U.S. Large Cap Multifactor Index ETF (FLQL) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FLQL
Zacks Investment Ideas feature highlights: Novo Nordisk, Eli Lilly and AbbVie
by Zacks Equity Research
Novo Nordisk, Eli Lilly and AbbVie have been highlighted in this Investment Ideas article.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $598.88, moving -0.07% from the previous trading session.
"Blockbuster Status": 3 Bios to Buy and Hold
by Andrew Rocco
The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
by Zacks Equity Research
Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023. The stock rises 7%.
Is First Trust Capital Strength ETF (FTCS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FTCS
NVS vs. LLY: Which Stock Is the Better Value Option?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
by Zacks Equity Research
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
Zacks Investment Ideas feature highlights: IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly
by Zacks Equity Research
IonQ, E.L.F Beauty, Amazon, Meta Platforms and Eli Lilly are part of the Zacks Investment Ideas article.
Here's How Much You'd Have If You Invested $1000 in Eli Lilly a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
4 Expert Tips for Navigating a Gap Down Market
by Andrew Rocco
Investors must learn to thrive in turbulent times. Stock Strategist Andrew Rocco provides 4 ways to hadle "tape bombs"
Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why
by Zacks Equity Research
Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.
Why Is Lilly (LLY) Up 6.4% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.